DE60321026D1 - In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3 - Google Patents

In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3

Info

Publication number
DE60321026D1
DE60321026D1 DE60321026T DE60321026T DE60321026D1 DE 60321026 D1 DE60321026 D1 DE 60321026D1 DE 60321026 T DE60321026 T DE 60321026T DE 60321026 T DE60321026 T DE 60321026T DE 60321026 D1 DE60321026 D1 DE 60321026D1
Authority
DE
Germany
Prior art keywords
oocytes
vitro
phosphodiesterase
hemmer
cytoplasmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60321026T
Other languages
English (en)
Inventor
Johan Smitz
Christian Grondahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Novo Nordisk AS
Original Assignee
Bayer Schering Pharma AG
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG, Novo Nordisk AS filed Critical Bayer Schering Pharma AG
Application granted granted Critical
Publication of DE60321026D1 publication Critical patent/DE60321026D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60321026T 2002-10-15 2003-10-15 In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3 Expired - Fee Related DE60321026D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201581 2002-10-15
PCT/DK2003/000703 WO2004035766A2 (en) 2002-10-15 2003-10-15 In vitro synchronisation of nuclear and cytoplasmatic maturation of oocytes involving addition and removal of phosphodiesterase type 3 inhibitor

Publications (1)

Publication Number Publication Date
DE60321026D1 true DE60321026D1 (de) 2008-06-26

Family

ID=32103846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321026T Expired - Fee Related DE60321026D1 (de) 2002-10-15 2003-10-15 In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3

Country Status (7)

Country Link
US (2) US20060051863A1 (de)
EP (1) EP1554016B1 (de)
JP (1) JP2006502717A (de)
AT (1) ATE395102T1 (de)
AU (1) AU2003273767A1 (de)
DE (1) DE60321026D1 (de)
WO (1) WO2004035766A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
CZ302232B6 (cs) * 2008-07-15 2011-01-05 Ceská zemedelská univerzita v Praze Zpusob zvýšení vývojové schopnosti rostoucích oocytu inhibicí kalcineurinu
CN102482644A (zh) * 2009-05-14 2012-05-30 阿德莱德研究和创新私人有限公司 用于卵母细胞的收集及成熟的方法
US10392601B2 (en) 2014-12-19 2019-08-27 Vrije Universiteit Brussel In Vitro maturation of a mammalian cumulus oocyte complex
WO2024024742A1 (ja) * 2022-07-25 2024-02-01 国立大学法人京都大学 霊長類の胎児卵巣細胞から卵胞を誘導する体外培養法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678506B1 (fr) * 1991-07-01 2000-03-10 Claude Ranoux Procede de fecondation en cycle spontane.
CA2265495A1 (en) * 1996-09-13 1998-03-19 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
EP1235899B1 (de) * 1999-11-25 2007-03-21 Novo Nordisk A/S Behandlung von menschlicher unfruchtbarkeit
WO2001076360A2 (en) * 2000-04-06 2001-10-18 Novo Nordisk A/S Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro

Also Published As

Publication number Publication date
US20080311656A1 (en) 2008-12-18
ATE395102T1 (de) 2008-05-15
WO2004035766A3 (en) 2004-06-03
US20060051863A1 (en) 2006-03-09
EP1554016A2 (de) 2005-07-20
AU2003273767A1 (en) 2004-05-04
WO2004035766A2 (en) 2004-04-29
JP2006502717A (ja) 2006-01-26
EP1554016B1 (de) 2008-05-14

Similar Documents

Publication Publication Date Title
ATE238428T1 (de) Enantioselective herstellung von pharmazeutisch aktiven sulfoxiden durch bioreduktion
DE69722027D1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
DE59805727D1 (de) Thiazolderivate, verfahren zur herstellung und verwendung
EA200201056A1 (ru) Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств
YU83602A (sh) Derivati fenilglicina
ATE72436T1 (de) 2-(methyl(4-piperidinyl)>-1,2,3,4-tetrahydro-9h pyrido(3,4-b>indolderivate, ihre herstellung und therapeutische verwendung.
DE69624500D1 (de) Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten
DE59808710D1 (de) Verfahren zur herstellung von 2-(3-pyrazolyl-oxymethylen)nitrobenzolen
DE60321026D1 (de) In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3
BR0109975A (pt) Método para produzir ansamitocinas
ATE293632T1 (de) Verfahren zur herstellung von alkylverbrückten ligandsystemen und übergangsmetallverbindungen
TW200621685A (en) Hydroxynaphthoic acid hydrazide compound and method for preparing the same
FI925801A0 (fi) Piperidyl-substituerade indoler
NO970473D0 (no) N-substituerte 3-azabicyklo (3.2.0)heptanderivater egnet som neuroleptika
ATE176459T1 (de) Verfahren zur herstellung von 2-(sustituierten benzoyl)-1,3 cyclohexandionen
ATE392413T1 (de) Verfahren zur herstellung von beta-alaninamiden
ATE487701T1 (de) Verfahren zur herstellung von iminostilbenderivaten
ATE324366T1 (de) Verfahren zur herstellung von 3-pyrrolin-2- carbonsäure-derivaten
ATE361272T1 (de) Verfahren zur herstellung von 3,3- diarylpropylaminen
ATE280769T1 (de) Verfahren zur herstellung von vitronectin- rezeptorantagonisten
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold
DE60134067D1 (de) Zwischenplatte zum Einsetzen in einem Schneidschlitz
ATE513824T1 (de) Verfahren zur herstellung von isothiocyanato-2,2- difluorbenzo-(1,3)-dioxolen
EA200001076A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
DE69916269D1 (de) Neues verfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee